Economic value of the dengue vaccine: A contingent valuation study

Abstract

Dengue has shown a fast growth worldwide. Therefore, this study aims to determine the Money Availability (DAP, in Spanish) in order to do a financial valuation of the people’s access to a dengue vaccine and the related factors. A contingent valuation cross-sectional study was conducted in order to assess the Money Availability and the related factors in the population of Piura, Perú. A hetero-applied questionnaire with a double binary-dichotomic format and discrete choice was used; it was applied in the mode of a personal interview. The analysis included 371 individuals. The highest Money Availability was S/. 210 (New Peruvian Sol, PEN). The variables associated with buying the vaccine were working as a health professional, having earned a college degree, having personal or family background of dengue. The vaccine pricing is a key factor in the development and standardization of this new market. The public health authorities must consider the financial evidence thus available when designing sustainable interventions for this new technology.